2023
Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non–muscle-invasive Bladder Cancer
Tan W, McElree I, Davaro F, Steinberg R, Bree K, Navai N, Dinney C, O'Donnell M, Li R, Kamat A, Packiam V. Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non–muscle-invasive Bladder Cancer. European Urology Oncology 2023, 6: 531-534. PMID: 37468392, DOI: 10.1016/j.euo.2023.06.011.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerBacillus Calmette-GuerinIntermediate-risk non-muscle-invasive bladder cancerInternational Bladder Cancer GroupBladder cancerIntermediate-riskMulti-institutional retrospective reviewBlue light cystoscopyCombination of docetaxelEvaluate oncological outcomesHigh-grade diseaseMedian follow-upCancer-specific mortalityTreatment groupsCancer control outcomesBladder cancer groupSequential gemcitabineChemotherapy combinationsOncological outcomesIntravesical gemcitabinePostoperative chemotherapyAdjuvant treatmentRetrospective reviewRecurrence rateCancer group
2022
Intermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group
Tan W, Steinberg G, Witjes J, Li R, Shariat S, Roupret M, Babjuk M, Bivalacqua T, Psutka S, Williams S, Cookson M, Palou J, Kamat A. Intermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. European Urology Oncology 2022, 5: 505-516. PMID: 35718695, DOI: 10.1016/j.euo.2022.05.005.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerInternational Bladder Cancer GroupBladder cancer groupManagement of patientsIntermediate-riskIntravesical treatmentCancer groupRisk factorsClinical trialsIntravesical chemotherapyMultifocal tumorsEarly recurrenceTumor sizeBladder cancerFrequent recurrenceHeterogeneous diseaseGrading systemCarcinoma in situStage of tumorPostoperative intravesical chemotherapyRandomized clinical trialsMaintenance BCGComparison of outcomesRecurrent diseaseClinical practice guidance
2021
Effects of Delayed Radical Prostatectomy and Active Surveillance on Localised Prostate Cancer—A Systematic Review and Meta-Analysis
Chan V, Tan W, Asif A, Ng A, Gbolahan O, Dinneen E, To W, Kadhim H, Premchand M, Burton O, Koe J, Wang N, Leow J, Giannarini G, Vasdev N, Shariat S, Enikeev D, Ng C, Teoh J. Effects of Delayed Radical Prostatectomy and Active Surveillance on Localised Prostate Cancer—A Systematic Review and Meta-Analysis. Cancers 2021, 13: 3274. PMID: 34208888, PMCID: PMC8268689, DOI: 10.3390/cancers13133274.Peer-Reviewed Original ResearchNeoadjuvant hormonal therapyDelayed radical prostatectomyHigh-risk patientsRandomised controlled trialsRadical prostatectomyImmediate RPOncological outcomesCancer-specific survivalIntermediate-risk patientsMeta-analysisNewcastle-Ottawa ScaleDelayed RPIntermediate-riskNon-randomised controlled studiesRisk of biasOverall survivalHormone therapyWatchful waitingExpectant managementActive surveillanceCancer surgeryPathological outcomesNewcastle-OttawaLow riskObservational study
2018
Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories
Mossanen M, Wang Y, Szymaniak J, Tan W, Huynh M, Preston M, Trinh Q, Sonpavde G, Kibel A, Chang S. Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. World Journal Of Urology 2018, 37: 2059-2065. PMID: 30446799, DOI: 10.1007/s00345-018-2550-x.Peer-Reviewed Original ResearchConceptsBladder cancerProgression to muscle-invasive diseaseNon-muscle-invasive bladder cancerHigh-risk disease patientsEORTC risk calculatorHigh-risk NMIBCManagement of NMIBCMuscle-invasive diseaseLow-risk tumorsBiologically heterogeneous diseaseHigh-risk diseaseSurveillance of patientsMethodsA Markov modelLong-term surveillanceHigh-risk groupPatient risk groupsOverall cost of careCost of surveillanceCost of careIntermediate-riskSurveillance cystoscopyExpensive malignanciesIndex patientPatient basisNMIBC